The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study
Open accessAbstract
OBJECTIVE: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome. DESIGN: Multicentre retrospective case-control study. SETTING: 23 hospitals in northern Germany. PARTICIPANTS: 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome. MAIN OUTCOME MEASURES: Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death. RESULTS: 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P = 0.03), fewer deaths (0% v 5%, p = 0.029), required no abdominal surgery, and excreted E coli for a shorter duration. CONCLUSIONS: Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome
Tarr, P. I., Gordon, C. A., & Chandler, W. L. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71144-2 · Cited by 1,774
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Epidemic Profile of Shiga-Toxin–Producing Escherichia coli O104:H4 Outbreak in Germany
Frank, C., Werber, D., Cramer, J. P., Askar, M., Faber, M., an der Heiden, M., Bernard, H., Fruth, A., Prager, R., Spode, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106483 · Cited by 1,139
Wong, C. S., Jelacic, S., Habeeb, R. L., Watkins, S. L., & Tarr, P. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422601 · Cited by 1,094
Origins of the E. coli Strain Causing an Outbreak of Hemolytic–Uremic Syndrome in Germany
Rasko, D. A., Webster, D. R., Sahl, J. W., Bashir, A., Boisen, N., Scheutz, F., Paxinos, E. E., Sebra, R., Chin, C.-S., Iliopoulos, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106920 · Cited by 823
Mellmann, A., Harmsen, D., Cummings, C. A., Zentz, E. B., Leopold, S. R., Rico, A., Prior, K., Szczepanowski, R., Ji, Y., Zhang, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022751 · Cited by 768
Bielaszewska, M., Mellmann, A., Zhang, W., Köck, R., Fruth, A., Bauwens, A., Peters, G., & Karch, H. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70165-7 · Cited by 767
Zhang, X., McDaniel, A. D., Wolf, L. E., Keusch, G. T., Waldor, M. K., & Acheson, D. W. K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315239 · Cited by 603
Szczepiorkowski, Z. M., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R., Schwartz, J., Shaz, B. H., Weinstein, R., Wirk, A., et al. (2007) · Journal of Clinical Apheresis · doi:10.1002/jca.20129 · Cited by 546
Cited by
Gavriilaki, E., Anagnostopoulos, A., & Mastellos, D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00337 · Cited by 106
Metadata
- Authors
- Menne, J., Nitschke, M., Stingele, R., Abu-Tair, M., Beneke, J., Bramstedt, J., Bremer, J. P., Brunkhorst, R., Busch, V., Dengler, R., Deuschl, G., Fellermann, K., Fickenscher, H., Gerigk, C., Goettsche, A., Greeve, J., Hafer, C., Hagenmuller, F., Haller, H., Herget-Rosenthal, S., Hertenstein, B., Hofmann, C., Lang, M., Kielstein, J. T., Klostermeier, U. C., Knobloch, J., Kuehbacher, M., Kunzendorf, U., Lehnert, H., Manns, M. P., Menne, T. F., Meyer, T. N., Michael, C., Munte, T., Neumann-Grutzeck, C., Nuernberger, J., Pavenstaedt, H., Ramazan, L., Renders, L., Repenthin, J., Ries, W., Rohr, A., Rump, L. C., Samuelsson, O., Sayk, F., Schmidt, B. M. W., Schnatter, S., Schocklmann, H., Schreiber, S., von Seydewitz, C. U., Steinhoff, J., Stracke, S., Suerbaum, S., van de Loo, A., Vischedyk, M., Weissenborn, K., Wellhoner, P., Wiesner, M., Zeissig, S., Buning, J., Schiffer, M., Kuehbacher, T., & on behalf of the EHEC-HUS consortium
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2012-07-19
- Volume
- 345
- Issue
- jul19 1
- Pages
- e4565-e4565
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2096322533
- Cited by
- 309
- References
- 27
- FWCI
- 15.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. https://app.cochat.ai/papers/10.1136/bmj.e4565
- The paper
- Menne, J., Nitschke, M., Stingele, R., Abu-Tair, M., Beneke, J., Bramstedt, J., Bremer, J. P., Brunkhorst, R., Busch, V., Dengler, R., Deuschl, G., Fellermann, K., Fickenscher, H., Gerigk, C., Goettsche, A., Greeve, J., Hafer, C., Hagenmuller, F., Haller, H., . . . on behalf of the EHEC-HUS consortium. (2012). Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. https://doi.org/10.1136/bmj.e4565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
